Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 4, 1998, Pages 327-335

  Eder, Joseph Paul ^a   Chan, Victor ^b   Wong, Julia ^a   Wong, Yee W ^b   Ara, Gulshan ^a   Northey, David ^a   Rizvi, Naiyer ^c   Teicher, Beverly A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

CPT 11; Irinotecan; Topoisomerase I; Topoisomerase II; Treatment sequence effects

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MESSENGER RNA;

ANIMAL MODEL; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL DEATH; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DOXORUBICIN; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RNA, MESSENGER;

EID: 0031875044     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050825     Document Type: Article

References (35)

1. Wang J (1991) DNA topoisomerases: why so many? J Biol Chem 266: 6659-6662
2. Holm CT, Gato T, Wang JC, Botstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553
3. Gasser S, Laroche T, Falquet J, Tour EBDL, Laemmli LJ (1986) Metaphase chromosome structure: involvement of topoisomerase II. J Mol Biol 188: 613-629
4. Adachi Y, Luke M, Laemmli UK (1991) Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell 64: 137-148
5. Champoux J (1990) Mechanistic aspects of type-I topoisomcrases. In: Wang J, Cozarelli N (eds) DNA topology and its biological effects. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1990, pp 217-242
6. Heck M, Earnshaw W (1986) Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103: 2569-2581
7. Caron P, Wang J (1993) DNA topoisomerases as a target of therapeutics: a structural overview. In: Andoh T, Ikeda H, Oguro M (eds) Molecular biology of DNA topoisomerases and its application to chemotherapy. CRC, Boca Raton, 1993, pp 1-18
8. Hsiang Y, Hertzberg R, Hecht S, Liu L (1985) Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerase II. J Biol Chem 260: 14873-14878
9. Kohn K, Pommier Y, Kerrigan D, Markovits J, Covey J (1987) Topoisomerase II as a target of anticancer drug action in mammalian cells. NCI Monogr 4: 61-71
10. Pommier Y, Kohn K (1989) Topoisomerase II inhibition by antitumor intercalators and demethyepipodophyllotoxins. In: Glazer R (ed) Developments in cancer chemotherapy. CRC, Boca Raton, 1989, pp 175-196
11. Tan K, Mattern M, Eng W-K, McCabe F, Johnson R (1989) Non-productive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735
12. Sugimoto J, Tsukahara S, Oh-hara T, Isoes T, Tsuiuo T (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by monoclonal antibody. Cancer Res 50: 6925-6930
13. Friche E, Danks M, Schmidt C, Beck W (1991) Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 51: 1129-1136
14. Kaufman S (1991) Antagonism between camptothecin and topoisomerase II directed chemotherapy agents in a human leukemia cell line. Cancer Res 51: 4213-4218
15. Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E III (1990) Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 17: 18-32
16. Teicher BA, Holden SA, Jacobs JL (1987) Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47: 513-518
17. Eder J, Chan V-W, Ng S-W, Rizvi N, Zacharoulis S, Teicher B, Schippner L (1995) DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 55: 6109-6116
18. Teicher BA, Rose CM (1984) Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223: 934-936
19. Deen DF, Williams ME (1979) Isobologram analysis of X-ray-BCNU interactions in vitro. Radiat Res 79: 483-491
20. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Oncol Biol Phys 15: 85-91
21. Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 28: 1-18
22. Dewey WC, Stone LE, Miller HH, Giblak RE (1971) Radiosensitization with 5-bromodeoxyuridine of Chinese hamster cells X-irradiated during different phases of the cell cycle. Radiat Res 47: 672-688
23. Teicher BA, Holden SA, Ara G, Liu J-TC, Robinson MF, Flodgren P, Dupuis N, Northey D (1993) Cyclooxygenase inhibitors: in vitro and in vivo effects on antitumor alkylating agents in the EMT-6 murine mammary carcinoma. Int J Oncol 2: 145-153
24. Teicher BA, Korbut TT, Menon K, Holden SA, Ara G (1994) Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 33: 515-522
25. Hendricks C, Rowinsky E, Grochow L, Donehower R, Kaufman S (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SKF 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278
26. Chan V, Ng S-W, Eder J, Schnipper L (1993) Molecular cloning and identification of a point mutation in the topoisomerase IIc DNA from an etoposide resistant Chinese hamster ovary cell line. J Biol Chem 268: 2160-2165
27. Andoh T, Ishii K, Suzuki Y, Kusunoki Y, Takemoto Y, Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569
28. Doyle L (1994) Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol [Suppl] 34: S32-40
29. Ando M, Eguchi K, Shinkai T (1996) Phase I study of sequentially administered CPT-11 and VP-16 for metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 15: 480
30. Goto K, Nishiwaki Y, Saijo T (1995) A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) trial. Proc Am Soc Clin Oncolol 14: 362
31. Beidler A, Cheng Y-C (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47: 907-914
32. Fu Q, Grill S, Chen H, Cheng Y-C (1997) The role of proteases in camptothecin-induced topoisomerase I downregulation (abstract). Proc Am Assoc Cancer Res 38: 15
33. Bissery M, Vrignaud P, Lavelle F, Chabot G (1996) Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7: 437-460
34. Kawato Y, Furuta T, Aonuma M (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198
35. O'Reilly S, Kennedy M, Rowinsky E, Donehower R (1995) Vinorelbine and the topoisomerase I inhibitors: current and potential roles in breast cancer chemotherapy. Breast Cancer Res Treat 33: 1-17